Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma

Peter E ClarkVanderbilt University Medical Center, Nashville, Tennessee, USAAbstract: Advanced renal cell carcinoma (RCC) remains a challenging, major health problem. Recent advances in understanding the fundamental biology underlying one form of RCC, ie, clear cell (or conventional) RCC, have opene...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Peter E Clark
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/3bbb7ac2bde54dc1b115219024a4f576
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3bbb7ac2bde54dc1b115219024a4f576
record_format	dspace
spelling	oai:doaj.org-article:3bbb7ac2bde54dc1b115219024a4f5762021-12-02T01:34:42ZRationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma1177-54751177-5491https://doaj.org/article/3bbb7ac2bde54dc1b115219024a4f5762010-06-01T00:00:00Zhttp://www.dovepress.com/rationale-for-targeted-therapies-and-potential-role-of-pazopanib-in-ad-a4688https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Peter E ClarkVanderbilt University Medical Center, Nashville, Tennessee, USAAbstract: Advanced renal cell carcinoma (RCC) remains a challenging, major health problem. Recent advances in understanding the fundamental biology underlying one form of RCC, ie, clear cell (or conventional) RCC, have opened the door to a series of targeted agents, such as the tyrosine kinase inhibitors (TKIs), which have become the standard of care in managing advanced clear cell RCC. Among the newest of these agents to receive Food and Drug Administration approval in this disease is pazopanib. This review will summarize what is known about the fundamental biology that underlies clear cell RCC, the data surrounding the previously approved targeted agents for this disease, including not only the TKIs but also the mTOR inhibitors and the vascular endothelial growth factor-specific agent, bevacizumab, and the newest TKI, pazopanib. It will also explore the potential role for pazopanib relative to the other available agents and where it may fit into the armamentarium for treatment of advanced/metastatic RCC.Keywords: pazopanib, targeted therapy, tyrosine kinase inhibitor, clear cell renal cell carcinoma Peter E ClarkDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2010, Iss default, Pp 187-197 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Peter E Clark Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
description	Peter E ClarkVanderbilt University Medical Center, Nashville, Tennessee, USAAbstract: Advanced renal cell carcinoma (RCC) remains a challenging, major health problem. Recent advances in understanding the fundamental biology underlying one form of RCC, ie, clear cell (or conventional) RCC, have opened the door to a series of targeted agents, such as the tyrosine kinase inhibitors (TKIs), which have become the standard of care in managing advanced clear cell RCC. Among the newest of these agents to receive Food and Drug Administration approval in this disease is pazopanib. This review will summarize what is known about the fundamental biology that underlies clear cell RCC, the data surrounding the previously approved targeted agents for this disease, including not only the TKIs but also the mTOR inhibitors and the vascular endothelial growth factor-specific agent, bevacizumab, and the newest TKI, pazopanib. It will also explore the potential role for pazopanib relative to the other available agents and where it may fit into the armamentarium for treatment of advanced/metastatic RCC.Keywords: pazopanib, targeted therapy, tyrosine kinase inhibitor, clear cell renal cell carcinoma
format	article
author	Peter E Clark
author_facet	Peter E Clark
author_sort	Peter E Clark
title	Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
title_short	Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
title_full	Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
title_fullStr	Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
title_full_unstemmed	Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
title_sort	rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/3bbb7ac2bde54dc1b115219024a4f576
work_keys_str_mv	AT petereclark rationalefortargetedtherapiesandpotentialroleofpazopanibinadvancedrenalcellcarcinoma
_version_	1718402950621036544

Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma

Ejemplares similares